Cabot (NYSE:CBT) Full Year 2024 Results
Key Financial Results
- Revenue: US$3.99b (up 1.6% from FY 2023).
- Net income: US$380.0m (down 13% from FY 2023).
- Profit margin: 9.5% (down from 11% in FY 2023). The decrease in margin was driven by higher expenses.
- EPS: US$6.82 (down from US$7.79 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cabot Earnings Insights
Looking ahead, revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in the US.
Performance of the American Chemicals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Cabot that we have uncovered.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:CBT
Cabot
Operates as a specialty chemicals and performance materials company.
Excellent balance sheet established dividend payer.
